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 Abstract 
 
Immunomodulatory properties of mesenchymal stem cells (MSC) are key components of their successful applications in clinical setting. 
However, treatments based on MSC immunomodulation need understanding of cell characteristics before cell transplantation. We used live-
imaging to test the suitability of the MSC motility as a parameter for quick prediction of the immunomodulatory potential of human MSC in 
regulating the activity of stimulated peripheral blood mononuclear cells (PBMC) in vitro. Bone marrow MSC, from various donors and in vitro 
passages, were cultured with or without stimulated PBMC. After seven days, immunomodulation was assessed by measuring PBMC 
proliferation, IgG production and cytokine secretion in MSC and PBMC monocultures and co-cultures, and results were correlated to MSC 
motility. In co-culture, we observed that MSC successfully inhibited PBMC activity, reducing PBMC proliferation and IgG production 
compared to PBMC monoculture. MSC modulated PBMC to reduce the secretion of TNFα and IL-10, increase IL-6, G-CSF and MCP-1, while 
GM-CSF was not affected. By live-imaging tracking of cell trajectories, we observed that fast moving MSC were inhibiting more efficiently 
stimulated PBMC compared to slow ones. In co-culture, fast MSC were more effective in inhibiting IgG production (~30% less IgG), and 
secreted higher levels of IL-10 (~10% increase) and GM-CSF (~20% increase) compared to slower cells. Furthermore, fast MSC in 
monocultures produced 2.3-fold more IL-6, 1.5-fold MCP-1 and 1.2-fold G-CSF in comparison to slower cells. In conclusion, live-imaging cell 
tracking allowed us to develop an indicative assay of the immune-regulatory potential of MSC prior to in vivo administration. 
 
 
of the MSC, for example tumor necrosis factor α (TNF-α), 
interleukin 1-β (IL1-β) or interferon-γ (IFN-γ) are required for the 
activation of MSC induced immunomodulation[17,18]. MSC were 
reported to mediate a shift from a Th1 driven response to rather an 
anti-inflammatory Th2 response[19] which is characterized by lower 
levels of interleukin-2 (IL-2), IFN-ϒ and TNF-α and higher 
concentrations of interleukin-4 (IL-4), IL-5, IL-10 and IL-13. MSC 
can also secrete interleukin-6 (IL-6) which was shown to inhibit the 
differentiation of monocytes into antigen presenting dendritic 
cells[20]. Furthermore, IL-6 produced by MSC promotes neutrophil 
survival and expansion when combined with granulocyte 
macrophage colony-stimulating factor (GM-CSF)[21]. Additionally, 
it was found that by producing monocyte chemoattractant protein-1 
(MCP-1 or CCL2), MSC are able to inhibit IgG production of 
plasma cells[22,23] and  induce T-cells apoptosis via the FAS ligand-
dependent FAS pathway[24].   
 
Despite all promising researches, clinical trials with autologous 
MSC transplantations can have uncertain outcomes, partially caused 
by the wide intra- and inter-donor variability of MSC 
populations[25]. Such variations include diverse differentiation 
potential, cell morphology[26] or cell motility. Nowadays, there is a 
consensus that MSC therapies would be better predictable and more 
reproducible if we could evaluate and then use only cells with 
standardized characteristics.   
 
We have demonstrated previously that in vitro MSC motility can be  
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Introduction 
 
Human mesenchymal stem cells (MSC) are multipotent stromal 
cells with the ability to undergo extensive proliferation[1,2], 
produce a large number of cytokines[3], and the potential to 
differentiate into several cell lineages, such as adipocytes, 
chondrocytes, myocytes and osteoblasts[4]. Because of these 
defining characteristics, MSC emerged as one of the favorite 
candidates for cell-based therapies and tissue engineering 
approaches. Clinical trials have shown the beneficial effects of 
MSC application in critical health conditions like myocardial 
infarction[5], spinal cord injuries[6] and liver cirrhosis[7]. 
Additionally to their tissue restorative capacity, MSC also showed 
extensive immunomodulatory effects[8] making them potentially 
applicable in the treatment of immune-related diseases, such as 
graft versus host disease[9], systemic lupus erythematosus and 
multiple sclerosis[10].  
 
The exact mechanism by which MSC regulate the immune system 
is still a matter of debate, but it is likely to be a co-effect of direct 
contact between cells and secretion of soluble factors. The 
complexity of the immunomodulatory mechanism is represented 
by the involvement of more than a dozen soluble factors which 
were shown to act on both innate and adaptive immune cells[11,12]. 
Among the most discussed secreted immunosuppressive factors 
are indoleamine-pyrrole 2,3-dioxygenase[13], prostaglandin E2[14], 
transforming growth factor-β[15] and nitric oxide[16]. Secretion of 
those   soluble   factors   is  dependent  on  the  microenvironment 
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a useful parameter to quickly characterize and distinguish the 
differentiation potential of MSC populations[27]. Despite the 
observation that MSC were moving randomly and without 
directionality, we could determine that slow moving MSC were more 
likely to be senescent when compared with fast moving ones. 
However, average moving cells outperformed the rest with their 
ability to differentiate showing that MSC motility is a good predictor 
for the differentiation potential. We then wanted to investigate if a 
correlation with the immunomodulatory capacity of MSC also exists. 
 
In this study, we tested the suitability of the MSC motility as a 
parameter for quick prediction of the immunomodulatory potential of 
the cells. We investigated by live-imaging microscopy the in vitro 
motility of human MSC isolated from different donors at various 
culture passages and correlated the velocity to their 
immunomodulatory capacities in co-culture with allogeneic peripheral 
blood mononuclear cells (PBMC). Immunomodulation was assessed 
by measuring the PBMC proliferation, IgG production and cytokine 
secretion (listed in Table 1) in the MSC and PBMC co-cultures and 
results were compared to PBMC and MSC monocultures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
 
Mesenchymal stem cells (MSC) isolation and expansion 
 
Bone marrow (BM) samples were harvested from the iliac crest of 
donors undergoing spine surgery. The study was ethically approved 
by the ethics committee of Canton of Lucerne (Study number: 730). 
Written informed consent was obtained from all the participants and 
this procedure was also approved by the approving body. MSC were 
isolated from BM of ten donors (4 females and 6 males; average age: 
43 years; range: 17-59 years). The BM aspirates were immediately 
resuspended in 3.8% sodium citrate and phosphate buffered saline 
(PBS, Applichem - Axonlab, Baden, Switzerland) and then filtered 
through a 100 µm cell strainer to remove clots (Falcon - Faust, 
Schaffhausen, Switzerland). Mononuclear cells were separated by H-
Lympholyte Cell Separation Media gradient centrifugation (density 
1.077 g/mL; Cedarlane - Bio Concept, Allschwil, Switzerland) in 
Leucosep tubes (Huberlab, Reinach, Switzerland) at 800 g for 15 
minutes, washed with PBS, centrifuged again at 210 g for 10 minutes 
and plated at a density of 1 × 105 cells/cm2 in tissue culture flasks 
(TPP – Faust) in α-MEM, supplemented with 10% fetal bovine serum 
(FBS) (both Amimed – Bio Concept), (100 units/mL) penicillin / (100 
mg/mL) streptomycin, 2.5 µg/ml amphotericin B (both Gibco – 
LuBioScience GmbH, Lucerne, Switzerland) at 37°C in a humid 
atmosphere containing 5% CO2. After two days, non-adherent cells 
were discarded, whereas adherent cells were cultured in growing 
medium consisting of DMEM/Ham’s F12, supplemented with 10% 
foetal bovine serum (FBS) (both Amimed), (100 units/mL) penicillin / 
(100 mg/mL) streptomycin (Pen-Strep), 2.5 µg/ml Amphotericin B 
(all Gibco) and 5 ng/ml  recombinant  basic  fibroblast  growth  factor  
 
 
 
 
(bFGF, Peprotech – LuBioScience), followed by media change three 
times per week. At 80% confluency, MSC were frozen and stored at -
150ºC. 
 
Phenotypic characterization of MSC 
 
Bone marrow-derived mononuclear cells (1 x 106 cells) were plated 
in 10 cm-Primaria cell-culture dishes (Falcon) and cultured with 
growing medium. After 14 days, cell colonies were washed with 
PBS, fixed with 100% methanol, and stained with Giemsa solution 
(all these reagents were from Applichem). 
 
Following cell culture expansion, CD44, CD90 and CD105 positive 
and CD14 negative MSC markers were analyzed by flow cytometry. 
Briefly, cells were incubated with CD14-FITC (NB100-77759, 
Novus Biological - LuBioScience), CD44-FITC (NBP1-41278, 
Novus Biological), CD90-FITC (NBP1-96125, Novus Biological) 
and CD105-FITC (MCA1557A488T, AbD Serotec - LuBioScience) 
antibodies in PBS for one hour at 4°C, washed and resuspended in 
PBS. Cell fluorescence was evaluated with FACScalibur flow 
cytometer (Becton Dickinson) and data were analyzed using FlowJo 
v.10.0 software (Treestar, Ashland, OR, USA). 
 
Peripheral blood mononuclear cells (PBMC) isolation and 
characterization 
 
Venous blood (45 ml) was collected from a healthy male donor (27 
years old) in S-Monovettes containing EDTA (S-Monovettes, 9 ml 
K3E; Sarstedt, Nümbrecht, Germany). Peripheral blood mononuclear 
cells (PBMC) were isolated by H-Lympholyte Cell Separation Media 
gradient centrifugation in a Leucosep tube at 800 g and room 
temperature, for 20 minutes. The PBMC-containing buffy coat was 
carefully retrieved and washed with PBS, followed by a 
centrifugation at 210 g and room temperature for 10 minutes. The 
obtained PBMC pellet was resuspended in RPMI-1640 medium 
(Amimed; Bio Concept) supplemented with 10% FBS, Pen-Strep and 
amphotericin B.  
 
Flow cytometric analysis of PBMC with CD4 (APC Mouse Anti-
Human CD4 Clone RPA-T4, BD Bioscience, Allschwil, Switzerland) 
and CD8 (PE Mouse Anti-Human CD8 Clone RPA-T8, BD 
Bioscience, Allschwil, Switzerland) surface markers was performed 
after seven days in co-culture with MSC and in PBMC monoculture. 
Cells were incubated with antibodies in PBS for 15 minutes at room 
temperature, washed and resuspended in PBS. Cell fluorescence was 
evaluated with FACScalibur flow cytometer and data were analyzed 
using FlowJo v.10.0 software. 
 
PBMC stimulation before co-culture 
 
PBMC were stimulated in a cocktail adapted from a                          
previous work[28], consisting of 60 ng/ml human recombinant 
interleukin-2 (IL-2), 25 ng/ml Interleukin-10 (IL-10), 100 ng/ml 
Interleukin-21 (IL-21) (all from BioBasic Inc.; Stephan Klee Trading 
and Consulting, Sissach, Switzerland), the synthetic unmethylated 
oligodeoxynucleotide deoxycytosine-deoxyguanosine (CpG2429: 
tcgtcgttttcggcggccgccg, 360 nM[29] Microsynth AG, Balgach, 
Switzerland) and 2.5 µg/ml pokeweed mitogen (Sigma-Aldrich 
Chemie GmbH, Buchs, Switzerland) in RPMI-1640 medium 
(Amimed; Bio Concept) + 10% FBS. After addition of the 
stimulating cocktail, PBMC were incubated overnight at 37°C in the 
incubator (5% CO2), then washed with PBS, centrifuged at 210 g at 
room temperature for 10 minutes, and re-suspended in media for co-
culture with MSC, or as a control. 
 
MSC and PBMC co-cultures 
 
MSC were split in three groups for co-culture with PBMC, in vitro 
cell  tracking   and  cell  metabolic  activity  (day 0).  To  prepare  co-  
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Table 1. List of analysed cytokines and their expression by MSC 
and PBMC during pro- and anti-inflammatory processes.  
 
Cell type Immunomodulation Cytokines [Ref] 
MSC 
Pro-Inflammatory IL-6[3, 33] 
Anti-Inflammatory IL-6[3, 33], MCP-1[20] 
PBMC 
Pro-Inflammatory TNF-α[38], IL-10[32] 
Anti-Inflammatory 
IL-6[33], IL-10[39], 
MCP-1[20], 
G-CSF[34, 40] 
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culture with PBMC, in vitro cell tracking and cell metabolic activity 
(day 0). To prepare co-culture with PBMC, MSC (2 x 104 cells/well) 
were seeded in 96-well plates (each donor in quadruplicate; flat 
bottom culture test plates; TPP) in growing medium, and left for 
plastic attachment for 4 hours. After the incubation time, growing 
medium was removed and stimulated and unstimulated (negative 
control) PBMC (1.5 x 105 cells/well) were co-cultured with MSC in a 
final volume of 300 µl/well of RPMI-1640 medium (Amimed; Bio 
Concept) supplemented with 10% FBS, (100 units/mL), Pen-Strep 
and amphotericin B. This co-culture was maintained for 7 days at 
37°C and 5% CO2.   
 
The ratio MSC:PBMC used (2:15) lies in range of previous work on 
immunosuppression[30]. To study the correlation between MSC 
immunomodulatory capacity and cell motility, our preliminary test 
showed that MSC inhibited more efficiently IgG production at the 
ratio of 2:15 than 1:15.   
 
Cell metabolic activity 
 
MSC (2 x 104 cells/well) were seeded in 96-well plates (each donor in 
triplicate; flat bottom culture test plates) in growing medium, left 
overnight to adhere to the plate and then the cell activity was assessed 
by resazurin reduction assay. MSC were incubated (day 1) in 
resazurin solution - 15 ng/mL resazurin, 2.5 ng/mL methylene blue, 
0.1 mM potassium ferricyanide, 0.1 mM potassium ferrocyanide (all 
Applichem) in growing medium without bFGF - for 6 hours and 
bottom well fluoresce absorbance was measured (λex= 535 nm and 
λem= 595 nm) using a Multimode Detector (DTX 880; Beckman 
Coulter, Nyon, Switzerland). 
 
In vitro cell tracking of MSC 
 
MSC (day 0) at in vitro passage 2-3 (n=7) and passage 6 (n=3) were 
plated at a density of 5.6 x 103 cells/cm2. After 3 hours, the 
movements of the adherent cells started to be recorded using an 
inverted phase-contrast microscope equipped with a high-sensitive 
camera (Olympus, Tokyo, Japan, http://www.olympus-global.com) at 
40X magnification. The interval between image acquisitions was 10 
minutes, using the Xcellence software program (Olympus) over a 24-
hour period. Video sequences were analyzed using ImageJ (NIH, 
Bethesda, MD, http://www.nih.gov/ij) and the plugin MTrackJ, which 
allows manual tracking of individual cell trails. Analyses were only 
made for cells moving within the plane of focus. The full length of 
the track was determined as the distance from the first point to the last 
point of the track, and the cell speed was measured as mm/day. We 
defined three representative groups for cell motility: slow moving 
MSC (0.1-0.2 mm/day), medium moving MSC (0.4-0.5 mm/day) and 
fast moving MSC (0.9-1.0 mm/day).  
 
PBMC proliferation assay 
 
Before stimulation, the isolated PBMC were stained with the 
fluorescent cell proliferation indicator CytoTell green (AAT 
Bioquest; LuBioScience) according to the manufactures protocol (20 
minutes incubation at room temperature in 1:600 diluted dye). The 
proliferative response is the percentage of cells that underwent at 
least 1 cell division.  The proliferative response of stimulated PBMC 
in co-cultures (n=10) and PBMC controls (n=1) was measured after 7 
days of incubation by flow cytometry (total of 30’000 events gated) 
using the intracellular CytoTell dilution method and the viability 
staining solution 7-AAD (eBioscience, Vienna, Austria). Data was 
analyzed using FlowJo software.  
 
IgG production assay 
 
After 7 days of incubation, the amount of secreted IgG antibody in 
the  supernatant t of  stimulated  co-cultures  (n=10),  PBMC  controls  
(n=1)  and  reference donors  (n=42;  age range:  23-58 years  (mean: 
42.8 years), and interquartile range IQR: 19) was quantified using a 
standard indirect ELISA, as follow: a 96-well plate (Nunc MaxiSorp, 
Fluka Chemie GmbH, Buchs, Switzerland) was coated with 1 ng/μL 
Protein A (LuBioScience) in PBS and incubated overnight at 4 °C, 
then washed with PBS with a plate washer (Beckman-Coulter, Nyon, 
Switzerland), and non-specific binding sites were blocked for 2 
hours at room temperature with blocking solution containing 5% 
TopBlock (LuBioScience) in PBS. After washing wells with PBS, 
cell culture supernatants (in triplicate for each donor) – cleared of 
cell debris by centrifugation and diluted threefold in PBS – were 
incubated for 2 hours at room temperature. Supernatants were then 
removed and the wells washed with PBS. Anti-human-IgG HRP-
conjugated secondary antibody (A80-119P Bethyl) diluted 1:5000 in 
blocking buffer was incubated for 1 hour at room temperature. IgG 
were determined by colorimetric measurement of the product of the 
enzymatic reaction mediated by HRP and o-phenylenediamine 
solution (15.3 mg/mL in citrate buffer, pH 5.0, Applichem – 
Axonlab). The reaction was stopped with 10% sulphuric acid. 
Absorbance was measured at 450 nm by DTX 880 Multimode 
Detector and IgG concentration (ng/mL) was determined from 
dilutions of purified human IgG (Bethyl – LuBioScience). 
 
Cytokine measurements 
 
The concentrations of cytokines and chemokines were analyzed in 
the supernatants of monoculture of MSC, and co-cultures of PBMC 
and MSC after 7 days incubation, by Bio-Plex Pro Cytokine, 
Chemokine and Growth Factor Assay (Bio-Rad Laboratories AG – 
Cressier, Switzerland). Data were collected and analyzed using a 
Bio-Rad Bio-Plex 200 instrument equipped with Bio-Plex Manager 
software (Bio-Rad). We measured the concentrations of interleukin-
2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 
(IL-10), granulocyte-colony stimulating factor (G-CSF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), 
monocyte chemoattractant protein 1 (MCP1) and tumor necrosis 
factor-alpha (TNF-α). 
 
Statistical analysis 
 
Cytokine and IgG concentrations, and proliferative responses were 
presented in bar charts as mean ± standard deviation (SD). Non-
parametric Mann-Whitney-Wilcoxon U-test for related variables was 
used to determine significant differences between samples, as a 
normal distribution of the data could not be guaranteed in this data 
set. For all tests, p < 0.05 was considered significant. Data analysis 
was performed with SPSS 24.0 for Windows (SPSS Inc.).   
 
Scatterplot were produced for culture concentration versus cell 
motility and smoothed via semiparametric regression models using 
the mixed model representation of penalized splines[31] as 
implemented in the SemiPar package in R (R Foundation for 
Statistical Computing, Vienna, Austria, http://www.r-project.org). 
Scatterplots and scatterplot smoothers were computed using R, 
version 2.14.2, for Windows (R Foundation for Statistical 
Computing). The confidence bands represent the certainty about the 
average trend. They capture the high variation in the data points. A 
single future prediction may not be well accordant to the suggested 
trend as interpolated; however, on average (of many predictions) it 
will be. 
 
Results 
 
Mesenchymal stem cells (MSC) characterization  
 
The bone marrow-isolated MSC were initially characterized by their 
elongated fibroblastic cellular phenotype (Figure 1A) and by their 
ability  to  generate colony forming units  (Figure 1B).  Furthermore,  
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Figure 1 MSC characterization was based on their 
peculiar fibroblast-like morphology (a, entire scale 
bar is 200 µm), ability to form colonies (stained 
with Giemsa; b) and expression of the positive 
markers CD44 (blue line), CD90 (green line), 
CD105 (orange line) and the negative marker 
CD14 (red line), tested by flow cytometry analysis 
(grey line = unstained control; c).  
 
Figure 2 Effects of stimulation cocktail on IgG 
production by PBMC. After seven days culture, the 
immuno-suppressive action of MSC on PBMC (a) 
was determined by measuring IgG production in 
stimulated (n=1) and unstimulated (n=1) PBMC 
monocultures, as well as in stimulated PBMC and 
MSC co-cultures (n=10; data represented as mean ± 
SD). On the bottom (b), comparison of IgG 
production between 42 donors (red bar = sample 
used to test the immuno-suppressive action of MSC).  
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MSC were characterized by flow cytometry analysis with the positive 
mesenchymal stem cell markers CD44, CD90, and CD105 and the 
negative monocyte-related marker CD14 (Figure 1C).  
 
IgG production by peripheral blood mononuclear cells (PBMC) in 
co-culture 
 
IgG production inhibition by MSC was tested on stimulated 
allogeneic PBMC in co-culture for 1 week (Figure 2A). Monocultures 
of MSC and PBMC (unstimulated or stimulated) served as a control. 
When co-cultured with MSC, stimulated PBMC decreased IgG 
production by 71%, while unstimulated PBMC IgG production was 
only a tenth of the stimulated control. Overall, PBMC production of 
IgG by the donor used in this project was very close (1.41 µg/ml) to 
the mean IgG production calculated out of 42 donors (1.37 µg/ml, 
Figure 2B). 
 
MSC modulated peripheral blood mononuclear cells (PBMC) activity 
in co-culture 
 
After seven days culture, stimulated (column A) and unstimulated 
(column B) PBMC, and stimulated  PBMC isolated from co-culture 
with MSC (column C) characterization was based on gating light 
scattered by cells (Figure 3: top row), CD4/CD8 ratio of T-cells 
(Figure 3: middle row) and cell morphology (Figure 3D). The 
viability (7-AAD assay) of the stimulated PBMC in monocultures 
was 95% and in co-cultures 96%. Forward (FSC) and side scattering 
profiles of stimulated PBMC showed a large spreading and activation 
of cells compared to unstimulated PBMC, and the results in 
monoculture were similar to co-culture with MSC. Analysis of mean 
FSC intensity showed that stimulated PBMC increased cell size of 
26% in comparison to unstimulated PBMC, and in co-culture with 
MSC only of 13%. CD4/CD8 ratios of unstimulated PBMC in 
monocultures and in co-cultures with MSC were identical (ratio = 
1.55), while stimulated PBMC in monoculture (ratio = 0.70) had a 
lower ratio compared to PBMC in co-culture (ratio = 1.09). 
Immunosuppression by MSC significantly prevented blastogenesis of 
stimulated PBMC already after three days of co-culture.  
 
The immunosuppressive effects of MSC on PBMC were determined 
by cell proliferative response of CD4+ T-cells and CD8+ T-cells 
(Figure 4: top rows). MSC inhibited the proliferation of both CD4+ 
(Figure 4D) and CD8+ T-cells (Figure. 4E), especially CD4+ T-cells 
(2.6-fold) in comparison to CD8+ T-cells (1.6-fold), while 
unstimulated PBMC were not dividing at all. 
 
We analyzed the concentration of eight inflammation-related 
cytokines in supernatants of controls (monocultures) and co-cultures 
(Figure 5), namely interleukin-6 (IL-6), granulocyte-colony 
stimulating factor (G-CSF), monocyte chemoattractant protein-1 
(MCP-1), interleukin-10 (IL-10), tumor necrosis factor (TNF-α) and 
granulocyte-macrophage colony-stimulating factor (GM-CSF). The 
concentrations of interleukin-2 and -4 (IL-2 and IL-4) were at or 
below the detection limit (data not shown). Co-culture of MSC with 
stimulated PBMC led to substantially increased IL-6 (Figure 5A), G-
CSF (Figure 5B) and MCP-1 (Figure 5C) concentrations. In 
comparison to stimulated PBMC monoculture, the average cytokine 
increase corresponded to 340-fold for IL-6, 600-fold for G-CSF and 
30-fold for MCP-1. Furthermore, the increase in G-CSF significantly 
correlated with in vitro culture passage of MSC. In stimulated 
PBMC:MSC co-culture, late passage MSC (P6) produced ~20% more 
G-CSF (p < 0.01) and  ~10% more IL-6 (p < 0.05) in comparison to 
early passage MSC (P2-P3) (data not shown). On the other hand, the 
presence of MSC inhibited the production of TNF-α (Figure 5D) and 
IL-10 (Figure 5E), 3.5- and 2.5-fold respectively. GM-CSF 
concentrations were not influenced by MSC (Figure 5F).  
 
MSC modulated the secretion of cytokines also in unstimulated 
PBMC  co-culture,  resulting  in a  400-fold  increase of  IL-6,  3-
fold increase of G-CSF and 5-fold increase of MCP-1 productions, 
compared to PBMC monoculture. Although IL-10 and TNF-α levels 
were unaffected by the MSC, GM-CSF was inhibited 1.8-fold in 
comparison to PBMC monoculture.  
 
Monoculture of MSC produced mostly IL-6 (2.7 ng/ml) followed by 
MCP-1 (2.3 ng/ml), and in lower amount GM-CSF (140 pg/ml), G-
CSF (50 pg/ml), TNF-α (23 pg/ml) and IL-10 (8.4 pg/ml).  Beside, 
compared to unstimulated cells, stimulation of PBMC in 
monoculture increased the production of TNF-α, IL-10 and GM-
CSF, and reduced MCP-1 (no changes in IL-6 and G-CSF levels). 
 
MSC in vitro motility and immunosuppressive potential  
 
We measured cell motility of MSC by time-lapse microscopy 
recording. For each donor, 70 MSC were tracked for 24 hours and 
their motility was plotted against proliferative response of CD4+ T-
cells (Figure 6A)  and CD8+ T-cells (Figure 6B), and IgG production 
(Figure 6C) by stimulated PBMC in co-culture.  We observed that 
mostly slow and fast moving MSC suppressed PBMC proliferation 
and IgG production, even though changes in proliferation were small 
in both cases. Slow moving MSC (0.1-0.2 mm/day) corresponded to 
CD4+ T-cells proliferative response of 11.6%, medium moving MSC 
(0.4-0.5 mm/day) of 12.2% and fast moving MSC (0.9-1.0 mm/day) 
of 11.9%. Furthermore,  slow moving MSC corresponded to CD8+ 
T-cells proliferative response of 38.4%, medium moving MSC of 
40.3% and fast moving MSC of 39.3%. 
 
PBMC produced in correspondence of slow MSC 80% IgG (356 
µg/ml), medium speed MSCs 100% (447 µg/ml) and fast moving 
MSCs 77% (345 µg/ml). The metabolic activity of MSC was plotted 
against cell motility (Figure 6D) and as expected fast moving MSC 
were also the most metabolically active. Compared to slow moving 
MSC, fast moving MSC were ~20% more active and medium 
moving ~10%. 
 
MSC in vitro motility in monoculture and cytokine concentrations  
 
The motility of MSC was plotted against cytokine concentrations in 
monocultures after one week of incubation (Figure 7). Fast moving 
stem cells produced 2.3-fold more IL-6 (Figure 7A), 1.2-fold more 
G-CSF (Figure 7B) and 1.5 fold-more MCP-1 (Figure 7C) than 
slower speed cells. On the other hand, GM-CSF (Figure 7E) was 
moderately reduced (6% difference between slow and fast) with 
increasing MSC speed. Secretion of IL-10 (Figure 7D) and TNF-α 
(Figure 7F) by MSC was low and independent of MSC motility.  
 
MSC in vitro motility influence on cytokine production in co-culture 
with stimulated PBMC 
 
In co-culture with stimulated PBMC, cell motility of MSC was 
plotted against cytokine productions after one week of incubation 
(Figure 8). Although IL-6 concentration was strongly increased 
compared to MSC monoculture, the difference between slow and fast 
MSC was only 1.6% (Figure 8A). Also, the concentrations of G-CSF 
(Figure 8B) and TNF-α (Figure 8F) were independent of MSC 
motility with a maximum difference of 3% respectively 4% between 
speeds. The production of MCP-1 (Figure 8C) was negatively 
correlated with MSC motility. In correspondence of slow MSC, 
MCP-1 production was 14% higher compared to fast MSC. On the 
other hand, increased IL-10 (Figure 8D) and GM-CSF (Figure 8E) 
were produced in correspondence of fast MSC. IL-10 and GM-CSF 
differences between slow and fast cells were 12% and 18% 
respectively.   
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Figure 3 After seven days culture, stimulated (column a) and 
unstimulated (column b) PBMC, and stimulated PBMC 
(column c), isolated from co-culture with MSC, were 
morphologically characterized. Images from a representative 
sample show light scattered gating of cells (side scatter, SSC, 
and forward scatter, FSC; top row) and CD4/CD8 ratio of T-
cells (middle row). On the bottom (d), microphotographs taken 
after three days show the presence or lack of lymphocyte blast 
formation in the same samples (entire scale bar is 100 µm). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 After seven days culture, effectiveness of immuno-
suppressive action of MSC on PBMC was determined by 
measuring cell proliferative response of stimulated (column a) 
and unstimulated (column b) PBMC, and stimulated PBMC 
(column c), isolated from co-culture with MSC. Top rows 
represent the proliferative response of CD4+ T-cells and CD8+ 
T-cells, in a representative sample (CytoTell staining). Results 
of the proliferative response of CD4+ T-cells (d) and CD8+ T-
cells (e) were summarized (stimulated (n=1) and unstimulated 
(n=1) PBMC monocultures, stimulated PBMC and MSC co-
cultures (n=10); data represented as mean ± SD).  
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Figure 5 MSC and PBMC had a reciprocal influence in the production of cytokines. After seven days, supernatant concentration of IL-6 (a), G-CSF (b), MCP-1 (c), TNF-α (d), 
IL-10  (e) and GM-CSF (f) was measured in MSC monoculture (n=10), stimulated (n=1) and unstimulated (n=1) PBMC monocultures, and co-culture with or without MSC 
(n=10). Data was acquired by Bio-Plex analysis and represented as mean ± SD (a = p<0.01; b = p<0.05).  
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Figure 6 Proliferative response of CD4+ T-cells (a) and CD8+ T-cells (b),  and IgG production (c) of stimulated PBMC in co-culture with MSC plotted against cell 
motility. The metabolic activity (d) of MSC in monoculture was also plotted against cell motility. Each row (70 cells) represents a MSC population. Abbreviations: O = 
single cells; — = penalized spline smoother; grey area = confidence band. (S = slow, M = middle, F = fast moving cells) 
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Figure 7 MSC monoculture concentration of IL-6 (a), G-CSF (b), MCP-1 (c), IL-10 (d), GM-CSF (e) ) and TNF-α (f)  plotted against cell motility. Each row (70 cells) represents a 
MSC population. Abbreviations: O = single cells; — = penalized spline smoother; grey area = confidence band. (S = slow, M = middle, F = fast moving cells) 
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Figure 8 Stimulated PBMC + MSC co-culture concentration of IL-6 (a), G-CSF (b), MCP-1 (c), IL-10 (d), GM-CSF (e) and TNF-α (f) plotted against cell motility. Each row (70 cells) 
represents a MSC population. Abbreviations: O = single cells; — = penalized spline smoother; grey area = confidence band. (S = slow, M = middle, F = fast moving cells) 
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Discussion 
 
In this study, we found that in vitro mesenchymal stem cells (MSC) 
motility correlates to some aspects of their immunosuppressive 
potential and production capacity of some cytokines. MSC 
immunomodulation effects were determined in mixed lymphocyte 
reaction assay, a broadly used method which provides direct contact 
and allows most fundamental interactions between cells. In co-
cultures with peripheral blood mononuclear cells (PBMC), PBMC 
blastogenesis was prevented in all MSC co-cultured samples and 
MSC successfully inhibited CD4+ T-cells and CD8+ T-cells 
proliferation but also the production of IgG. We stratified the MSC 
populations according to our empirical observations in three 
representative cell motility groups: slow moving (0.1-0.2 mm/day), 
medium moving (0.4-0.5 mm/day) and fast moving (0.9-1.0 mm/day). 
In co-culture with PBMC, fast moving MSC inhibited more 
effectively IgG production and proliferation of PBMC in comparison 
to slower cells, and were the most metabolically active. Interestingly, 
in the case of PBMC co-cultured with fast MSC, reduced secretion of 
G-CSF and TNF-α were observed, along with increased IL-10 
secretion. This particular combination of cytokine secretion is 
peculiar of M2 phenotype of macrophages (involved in parasite 
control, tissue remodelling, immune regulation and phagocytic 
activity), which are characterized by higher anti-inflammatory 
potential compared to M1 macrophages (producing pro-inflammatory 
cytokines, mediating resistance to pathogens and promoting Th1 
responses)[32]. The ability of MSCs to shift macrophages toward an 
M2 phenotype in vitro has been already described[33], and our data on  
secretion of cytokines suggest that fast moving MSC correlate better 
to M2 phenotype shift. Cytokine expression analysis of MSC in 
monoculture showed that IL-6 and MCP-1 were secreted in large 
amount by faster cells compared to slower ones. As a limitation, we 
cannot discuss properly the secretion origins of MCP-1 in co-cultures 
because in our experimental setting we cannot discriminate which 
type of cell – MSC or PBMC – produced this cytokine.  
 
Our results suggest that within the same MSC population, sub-groups 
of cells have different roles in modulating the action of PBMC. There 
might be a possibility that the observed intra-donor variability of 
MSC motility extrapolates even to the stem cell variability between 
people. This speculation is supported by the observation that MSC 
isolated from patients with multiple sclerosis had functional 
differences compared to healthy controls, such as reduced anti-
proliferative capacity and lower secretion of anti-inflammatory 
cytokines[34]. The dynamics occurring between sub-populations of 
MSC with different cell motility may play an important role for their 
overall immune-regulatory capacity. To better understand these 
dynamics, we also investigated the release of cytokines and 
chemokines by MSC, which are known to play a key role in the 
suppressive signalling. 
 
Despite the complex nature of cytokine signalling, in co-cultures we 
could discriminate distinct responses related to MSC regulatory 
abilities. The correlation between MSC motility and 
immunomodulation was based on the measurement in culture medium 
of the cytokines IL-2, IL-4, IL-6, IL-10, TNF-α, G-CSF, GM-CSF 
and MCP-1, shown previously to be relevant because of their anti- 
and pro-inflammatory properties and expression by both MSC and 
PBMC (Table 1). Stimulated PBMC secreted large amount of IL-10, 
TNF-α and GM-CSF, while unstimulated PBMC produced mostly 
MCP-1 and GM-CSF. On the other hand, MSC in monocultures 
produced only relevant amount of MCP-1 and IL-6, and negligible 
quantity of the other cytokines, as previously described in the 
literature[35]. No cross-talk from the cytokines used in the stimulation 
cocktail      was     expected     since    the     pre-stimulated     PBMC 
were thoroughly washed ahead of their culturing.  
 
The immuno-suppressive action of MSC in co-culture with 
stimulated PBMC was demonstrated by the reduced PBMC secretion 
of pro-inflammatory cytokines (TNF-α) and increased MSC 
secretion of anti-inflammatory cytokines (IL-6, MCP-1 and G-CSF). 
Unexpectedly, the anti-inflammatory cytokine IL-10 was reduced by 
MSC, but a growing body of evidence shows that IL-10 action is 
multifactorial and in some settings may not be the previously thought 
inhibitor of immune functions[36,37]. Furthermore, IL-10 was 
described to stimulate IgG isotype switch in B-lymphocytes[38] and 
ultimately has been used as a main component of PBMC stimulation 
cocktail. The secretion by stimulated PBMC of another important 
cytokine, IL-6, was observed in co-culture with MSC, indicating an 
anti-inflammatory action by IL-6 in this particular setting[39,40]. Also 
MCP-1 had an anti-inflammatory pattern, where its expression was 
higher in both co-cultures compared to monocultures. Not 
surprisingly, the other immuno-modulatory molecule G-CSF – which 
has also been proven to have an anti-inflammatory role[41] – was 
massively upregulated when MSC were co-culture with stimulated 
PBMC. In vivo, G-CSF is a hematopoietic cytokine produced by 
monocytes, macrophages, fibroblasts, and endothelial cells which 
regulates neutrophil mobilization during infections and 
inflammations[42]. We speculate that such a large production of G-
CSF was triggered from MSC, what might mimic the innate 
immune-activation – namely instant blood-mediated inflammatory 
and anti-inflammatory reactions – observed in vivo after systemic 
injection of MSC[43]. As a matter of evidence[44], in vitro long-term 
expansion of MSC has been related to impaired inflammatory 
modulation and we observed the same pattern: co-cultures with high 
passage MSC (P6) were significantly producing more IL-6 and G-
CSF than early passage MSC (P2 and P3). Similar results were 
reflected in a phase II clinical trial for the treatment of acute graft 
versus host disease (GvHD) where MSC transplantation failed to 
prevent the development of grade II acute GvHD in one patient 
because increased gene expression of IL-6 and CSF which possibly 
may have promoted T- and B-cell proliferation and macrophages 
activation[45]. Among all cytokines analysed, GM-CSF concentration 
was not affected by the presence of MSC and we concluded that it 
might not be involved in the immunomodulation process. 
 
The limitation of our study is the experimental application of a single 
PBMC donor. However,  the aim of this study was to compare MSC 
behaviours without introducing further confounders. Indeed, the 
results presented in this work focus on MSC cell motility and 
immunomodulatory potential rather than the effects of multiple 
sources of PBMC. To avoid misleading results, the choice of the 
PBMC donor was based on IgG production and selecting the closest 
donor to the mean value of the investigated population. Further 
limitation, is that we did not examine neither the functional 
outcomes that cell motility might have on specific immune cell 
subsets, nor the correlation of  MSC hypoimmunogenicity to in vitro 
cell tracking. 
 
Conclusion 
 
We showed that MSC motility is a prospective indicator for MSC 
immunomodulatory potential. Although the heterogeneity of cell 
motility in MSC populations reduce the accuracy of the proposed 
method, it can be fruitfully used to indicate the overall potential of 
cell populations, especially in those with lower variability. In 
monoculture, fast MSC were more metabolically active and 
produced larger amounts of G-CSF, IL-6 and MCP-1. In co-culture 
with stimulated PBMC, fast MSC inhibited more efficiently IgG 
production, and  correlated  with   higher  IL-10  concentrations. The 
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process of standardization of cell production – i.e. MSC extraction, 
expansion and administration – is fundamental in the application of 
MSC as a treatment. We believe that in vitro cell tracking can 
contribute to a better understanding of the immunomodulatory 
properties of MSC, beyond the standard MSC molecular markers. In 
combination with the previously demonstrated predictive value of 
live-imaging for differentiation potential[27], we think that the 
measurement of cell motility is a fast assay which can be used alone 
or complementary to other tests in order to improve the prediction of 
clinical outcomes. 
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